EXTI - only public co. developing liver device Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : EXTI - only public co. developing liver device

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Danny Kim who started this subject	7/5/2004 11:22:51 AM
From: Tradenride	of 1063

Posted on RB April 28 2004 From a TC with Mr. Steen this afternoon: - MCT's immortalized cell lines do not have 100 % the same characteristics as fresh human hepatocytes, but they behave very similar in many ways. - Pharmaceutical companies need them for use in early stage of drug discovery - Pfizer, Roche and other companies are already using them - He is very positive about the use of these cells in the long run - During the last 3 to 5 years Pharmaceutical companies came to the conclusion that induction studies are an almost perfect prediction for inhibition studies (Hope this makes sense, but that's what I think he meant to say) - I suggested that after I had visited their website I had the impression these immortalized hepatocytes must be their "top-product". His answer was very clear: "yes" I was very glad to hear all of this. I hope the small rise in revenues from the last Q means Xenotech is starting to pay % on sales to MCT. Regards,

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next